Troxerutin capsules 300 mg. №60

$22.30

Symptomatic treatment of such diseases: pre-varicose and varicose syndrome, varicose ulcers; superficial thrombophlebitis, phlebitis and postphlebitis states; chronic venous insufficiency; hemorrhoids; diabetic retinopathy, in complex therapy; swelling and pain with injuries and varicose veins; varicose dermatitis; concussion, sprains, dislocations, symptoms of muscle crumps (convulsive contraction of the calf muscles) – a combined treatment.

Category:

Description

Composition and form of release
Active ingredients: troxerutin (300 mg).
Troxerutin Zentiva is produced in capsule form.
Pharmacological properties
It is a venoprotective agent. It has venotonic, anti-inflammatory, anti-edematous, angioprotective effect, reduces capillary permeability, fragility. The pharmacodynamic properties of the drug are associated with the participation of bioflavonoids in redox processes. By suppressing hyaluronidase, it stabilizes the hyaluronic acid of the cell membranes and reduces their permeability. Due to its antioxidant activity, it prevents the oxidation of ascorbic acid, lipids, adrenaline. Reduces permeability, fragility of capillaries, prevents damage to the basement membrane of endothelial cells when exposed to various damaging factors. Increases the density of the walls of blood vessels, reduces the exudation of the liquid part of the plasma, diapedesis of blood cells. Inhibits aggregation, increases the degree of erythrocyte deformation.
Indications
Troxerutin Zentiva is used:

  • with varicose veins;
  •  with chronic venous insufficiency with such manifestations as trophic skin lesions (trophic ulcers, dermatitis), heaviness in the legs;
  •  with superficial thrombophlebitis, periphlebitis;
  •  with hemorrhoids;
  •  with post-thrombotic syndrome;
  •  with post-traumatic edema, hematoma;
  •  for the prevention of complications after removal of varicose veins of the lower extremities and / or sclerotherapy;
  •  as part of the complex therapy of retinopathy in patients with arterial hypertension, diabetes mellitus, atherosclerosis.

Contraindications
Troxerutin Zentiva does not apply:

  •  in case of allergy to the active ingredient (methylethylpyridinol);
  •  with intolerance to auxiliary components;
  •  with gastric ulcer, duodenal ulcer, chronic gastritis in the acute phase;
  •  during pregnancy (in the first trimester);
  •  with breastfeeding;
  •  children under 18 years old.

With caution: in chronic renal failure.
Application during pregnancy and lactation
Use in the first trimester of pregnancy is contraindicated. It is allowed to use it in the II and III trimesters of pregnancy only by the decision of the doctor.
There are no data on the excretion of troxerutin in breast milk; therefore, its use during breastfeeding is not recommended.
Method of administration and dosage
Troxerutin Zentiva is used orally with meals.
The recommended starting dose is 300 mg three times a day. The effect usually develops within two weeks.
Further, therapy is continued at the same dose or reduced to an average therapeutic (300 mg twice a day) or suspended.
The dose can be increased if necessary. The course of treatment is 3-4 weeks.
Maintenance therapy – 300 mg once a day for 3-4 weeks.
Overdose
Symptoms: agitation, headache, nausea, “hot flashes” of blood to the face.
Treatment: gastric lavage, intake of enterosorbents (within an hour after administration), symptomatic treatment.
Side effects
Immune disorders: hypersensitivity reactions.
Neurological disorders: headache.
Vascular disorders: “hot flashes” of blood to the face.
Gastrointestinal disorders: stomach pain, nausea, diarrhea, vomiting, flatulence, erosive and ulcerative lesions.
Dermatological disorders: erythema, skin rash, pruritus.
Storage conditions and periods
Store Troxerutin Zentiva in its original packaging at temperatures up to + 25 ° C. The shelf life is three years.
The use of the drug after the expiration date indicated on the package is prohibited.
Parents need to ensure the safety of their children by excluding their access to medicine.